Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors

Krupali Desai(University of Pennsylvania), Philip Gehrman(California University of Pennsylvania), Sharon X. Xie(Memorial Sloan Kettering Cancer Center), Angela DeMichele(University of Pennsylvania), Jun J. Mao(Memorial Sloan Kettering Cancer Center), Qing Li(Fudan University), Irene Su(University of California San Diego)
Supportive Care in Cancer
May 14, 2012
10.1007/s00520-012-1490-z
Cited by 129

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
|Cell|2017|448
A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors
|Sleep Medicine Reviews|2015|376